The research service aims to analyse and assess the Therapeutic Monoclonal Antibodies market in Europe. This is performed by analysing the key trends and dynamics shaping the industry sector in correlation with the market drivers and restraints. With several key blockbuster drugs losing patent protection and an immense rise in the rate of disease incidences, the use of monoclonal antibodies for therapeutics has been on the increase. The tendency towards biologics has been on the increase during the past decade. This research service provides an in-depth knowledge of the key European markets by presenting significant growth opportunities for the existing drugs and those in the pipeline until 2016.